Xeris Pharmaceuticals Inc Stock News

If you're looking to gain an edge in the stock market today, you've got to have more than a list of penny stocks to watch. You need to understand how to use the wild volatility that has been created t

Xeris Biopharma reports notable revenue growth in Q2 2023 for its main products, Gvoke, Keveyis, and Recorlev. The company's expenses have also increased, with a rise in the cost of goods sold and res

Xeris Biopharma has reported another quarter of record revenue driven by continued strong demand for the biopharmaceutical company's products Gvoke, Keveyis, and Recorlev. For the quarter which ended

Xeris Biopharma said it has shipped more than 1 million units of Gvoke, its ready-to-use liquid glucagon for the treatment of severe hypoglycemia in adults and children aged two years and older with d

Xeris Biopharma Holdings (NASDAQ:XERS) told investors that the first participant has been dosed in a multi-center, open-label, Phase 2 study of XP-8121 (levothyroxine sodium) for the treatment of adu

Xeris Biopharma Holdings Inc is a growing healthcare company with strong revenue growth and a solid balance sheet, making it an attractive investment option. XERS has a range of successful products, s

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q1 2023 Earnings Conference Call May 9, 2023 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations, and Corporate Commun

Xeris Biopharma Holdings (NASDAQ:XERS) has started 2023 strongly, achieving record revenue during the first quarter.   For the quarter ended March 31, 2023, revenue rose 50.4% to $33.2 million from $

Xeris Biopharma Holdings (NASDAQ:XERS) said it has received a US patent covering formulations in its Gvoke product line used to treat severe hypoglycemia.  The patent issued by the US Patent and Tr

Xeris Biopharma Holdings (NASDAQ:XERS) told investors it has entered into a platform research evaluation collaboration and option agreement with Regeneron Pharmaceuticals Inc. Under the terms of the a

Xeris Biopharma Holdings (NASDAQ:XERS) Inc has announced the appointment of Ricki Fairley to its board of directors on March 27, 2023, increasing the size of the company's board to nine members. The g

Xeris Biopharma Holdings Inc (NASDAQ:XERS) posted record revenue growth for the fourth quarter and full-year 2022 and has issued bullish 2023 financial guidance. In the results statement, Paul R.

Xeris Biopharma expects to report record net product revenue for 2022 thanks to strong growth across their portfolio of approved products. Xeris believes they are still on track to hit its goal of cas

Xeris Biopharma Holdings (NASDAQ:XERS) Inc revealed that the Food and Drug Administration (FDA) granted its subsidiary Xeris Pharmaceuticals Inc, orphan-drug exclusivity (ODE) for Recorlev (levoketoco

Penny stocks fueled by news catalysts this week. The post 5 Hot Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.